接受6个月一次辅助唑来膦酸输注的次数是否影响早期乳腺癌的治疗疗效?ABCSG-12研究的亚组分析
该研究基于ABCSG-12试验的长期结局数据,评估早期乳腺癌患者接受辅助唑来膦酸输注次数对疗效的影响。纳入至少接受1次唑来膦酸输注的725例患者,从3年界标开始分析,结果显示接受≤6次与≥7次输注的患者在无病生存和总生存上无统计学显著差异。作者认为无证据表明减少唑来膦酸输注次数会降低辅助疗效,需进一步研究确定最佳方案。
要点
- 接受≤6次与≥7次唑来膦酸输注的患者无病生存和总生存无统计学显著差异。
- 研究基于ABCSG-12试验中至少接受1次唑来膦酸输注的725例患者。
- 作者认为无证据表明减少输注次数与辅助疗效降低相关,需进一步研究最佳方案。
核心结论
- 与转移性骨病中尝试缩短治疗疗程的努力类似,无证据表明减少唑来膦酸输注次数与辅助疗效降低相关。
- 需要进一步研究以确定辅助骨靶向治疗的最佳方案。
研究设计与样本
- ABCSG-12试验于1999年至2006年随机分配1803例激素受体阳性早期乳腺癌接受卵巢功能抑制的患者,采用2×2析因设计,接受每6个月4 mg唑来膦酸或不接受(同时接受他莫昔芬或阿那曲唑)。
- 本亚组研究评估唑来膦酸输注次数对乳腺癌特异性结局的影响,假设在至少接受1次唑来膦酸输注的患者中输注次数对结局无影响。
- 采用Cox模型和Kaplan-Meier曲线从3年界标开始分析至事件时间终点,骨密度分析仅限于参与骨密度亚研究的患者。
主要发现
- 725例至少接受1次唑来膦酸输注的患者纳入至事件时间分析。
- 接受≤6次唑来膦酸输注的患者(n=170)与接受≥7次输注的患者(n=555)相比,无病生存和总生存均无统计学显著差异。
局限性
- 需要进一步研究以确定辅助骨靶向治疗的最佳方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple regimens evaluated, there was no signal of varying efficacy with type, dose/dose intensity of bisphosphonate administration. We evaluated the effect of early treatment cessation using long-term outcome data from the ABCSG-12 trial. PATIENTS AND METHODS: ABCSG-12 randomized 1803 hormone-receptor positive EBC patients on ovarian suppression between 1999 and 2006 to receive 4 mg zoledronic acid 6-monthly or not (and tamoxifen or anastrozole, 2:2 factorial design). In the current study, we evaluated whether the number of zoledronate infusions had an impact on breast cancer-specific outcomes. We hypothesized that amongst patients who received at least one zoledronate infusion, the number of infusions had no effect on outcomes. Time-to-event endpoints were analysed with Cox models and Kaplan Meier curves starting from a 3-year landmark. BMD analysis was restricted to patients who participated in the BMD sub-study. RESULTS: 725 patients who received at least one zoledronate infusion were included in the time-to-event analysis. There was no statistically significant difference in disease-free or overall survival in the patients who received ≤6 zoledronate infusions (n = 170) compared to those who received ≥7 zoledronate infusions (n = 555). CONCLUSIONS: Comparable to efforts to de-escalate treatment duration in metastatic bone disease, there was no evidence to indicate that a reduced number of zoledronate infusions is associated with reduced adjuvant efficacy. Further studies to define optimal regimens of adjuvant bone-targeted therapies are required.
引用
- Beltran-Bless AA, Clemons MJ, Fesl C, et al. Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12. Eur J Cancer. 2022. PMID: 36592505. doi:10.1016/j.ejca.2022.12.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。